159 related articles for article (PubMed ID: 33574659)
1. Real-Time Monitoring and Point-of-Care Testing: A Review of the Current Landscape of PrEP Adherence Monitoring.
Hannaford A; Arens Y; Koenig H
Patient Prefer Adherence; 2021; 15():259-269. PubMed ID: 33574659
[TBL] [Abstract][Full Text] [Related]
2. Perspectives on the utility and interest in a point-of-care urine tenofovir test for adherence to HIV pre-exposure prophylaxis and antiretroviral therapy: an exploratory qualitative assessment among U.S. clients and providers.
Bardon AR; Simoni JM; Layman LM; Stekler JD; Drain PK
AIDS Res Ther; 2020 Aug; 17(1):50. PubMed ID: 32762713
[TBL] [Abstract][Full Text] [Related]
3. Testing a Real-Time Tenofovir Urine Adherence Assay for Monitoring and Providing Feedback to Preexposure Prophylaxis in Kenya (PUMA): Protocol for a Pilot Randomized Controlled Trial.
Drain P; Ngure K; Mugo N; Spinelli M; Chatterjee P; Bacchetti P; Glidden D; Baeten J; Gandhi M
JMIR Res Protoc; 2020 Apr; 9(4):e15029. PubMed ID: 32238341
[TBL] [Abstract][Full Text] [Related]
4. Real-time monitoring and just-in-time intervention for adherence to pre-exposure prophylaxis among men who have sex with men in China: a multicentre RCT study protocol.
Jin X; Wang H; Li H; Chu Z; Zhang J; Hu Q; Lv W; Huang X; Chen Y; Wang H; He X; Zhang L; Hu Z; Bao R; Li S; Ding H; Geng W; Jiang Y; Shang H; Xu J;
BMC Public Health; 2020 Jul; 20(1):1160. PubMed ID: 32709230
[TBL] [Abstract][Full Text] [Related]
5. Point-of-care and Near Real-time Testing for Antiretroviral Adherence Monitoring to HIV Treatment and Prevention.
Drain PK; Bardon AR; Simoni JM; Cressey TR; Anderson P; Sevenler D; Olanrewaju AO; Gandhi M; Celum C
Curr HIV/AIDS Rep; 2020 Oct; 17(5):487-498. PubMed ID: 32627120
[TBL] [Abstract][Full Text] [Related]
6. PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: Results from HPTN 082, a randomized controlled trial.
Celum C; Hosek S; Tsholwana M; Kassim S; Mukaka S; Dye BJ; Pathak S; Mgodi N; Bekker LG; Donnell DJ; Wilson E; Yuha K; Anderson PL; Agyei Y; Noble H; Rose SM; Baeten JM; Fogel JM; Adeyeye A; Wiesner L; Rooney J; Delany-Moretlwe S
PLoS Med; 2021 Jun; 18(6):e1003670. PubMed ID: 34143779
[TBL] [Abstract][Full Text] [Related]
7. Adherence to Daily Oral TDF/FTC for PrEP in Community Health Center Populations: The Sustainable Health Center Implementation PrEP Pilot (SHIPP) Study.
Smith DK; Rawlings MK; Glick N; Mena L; Coleman M; Houlberg M; McCallister S; Wiener J
AIDS Behav; 2022 Feb; 26(2):350-360. PubMed ID: 34347198
[TBL] [Abstract][Full Text] [Related]
8. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study.
Grinsztejn B; Hoagland B; Moreira RI; Kallas EG; Madruga JV; Goulart S; Leite IC; Freitas L; Martins LMS; Torres TS; Vasconcelos R; De Boni RB; Anderson PL; Liu A; Luz PM; Veloso VG;
Lancet HIV; 2018 Mar; 5(3):e136-e145. PubMed ID: 29467098
[TBL] [Abstract][Full Text] [Related]
9. Adherence to Pre-Exposure Prophylaxis for HIV Prevention in a Clinical Setting.
Montgomery MC; Oldenburg CE; Nunn AS; Mena L; Anderson P; Liegler T; Mayer KH; Patel R; Almonte A; Chan PA
PLoS One; 2016; 11(6):e0157742. PubMed ID: 27333000
[TBL] [Abstract][Full Text] [Related]
10. Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa.
Haberer JE; Baeten JM; Campbell J; Wangisi J; Katabira E; Ronald A; Tumwesigye E; Psaros C; Safren SA; Ware NC; Thomas KK; Donnell D; Krows M; Kidoguchi L; Celum C; Bangsberg DR
PLoS Med; 2013; 10(9):e1001511. PubMed ID: 24058300
[TBL] [Abstract][Full Text] [Related]
11. Plasma Tenofovir Levels to Support Adherence to TDF/FTC Preexposure Prophylaxis for HIV Prevention in MSM in Los Angeles, California.
Landovitz RJ; Beymer M; Kofron R; Amico KR; Psaros C; Bushman L; Anderson PL; Flynn R; Lee DP; Bolan RK; Jordan WC; Tseng CH; Dierst-Davies R; Rooney J; Wohl AR
J Acquir Immune Defic Syndr; 2017 Dec; 76(5):501-511. PubMed ID: 28902074
[TBL] [Abstract][Full Text] [Related]
12. Current concepts for PrEP adherence in the PrEP revolution: from clinical trials to routine practice.
Haberer JE
Curr Opin HIV AIDS; 2016 Jan; 11(1):10-7. PubMed ID: 26633638
[TBL] [Abstract][Full Text] [Related]
13. Challenges to PrEP use and perceptions of urine tenofovir adherence monitoring reported by individuals on PrEP.
Hunt T; Lalley-Chareczko L; Daughtridge G; Swyryn M; Koenig H
AIDS Care; 2019 Oct; 31(10):1203-1206. PubMed ID: 30821473
[TBL] [Abstract][Full Text] [Related]
14. Factors associated with the uptake of and adherence to HIV pre-exposure prophylaxis in people who have injected drugs: an observational, open-label extension of the Bangkok Tenofovir Study.
Martin M; Vanichseni S; Suntharasamai P; Sangkum U; Mock PA; Chaipung B; Worrajittanon D; Leethochawalit M; Chiamwongpaet S; Kittimunkong S; Gvetadze RJ; McNicholl JM; Paxton LA; Curlin ME; Holtz TH; Samandari T; Choopanya K;
Lancet HIV; 2017 Feb; 4(2):e59-e66. PubMed ID: 27866873
[TBL] [Abstract][Full Text] [Related]
15. Risk-Taking Behaviors and Adherence to HIV Pre-Exposure Prophylaxis in Users of Geosocial Networking Apps: Real-World, Multicenter Study.
Wang H; Zhang J; Chu Z; Hu Q; Dong W; Huang X; Chen Y; Wang H; He X; Zhang L; Hu Z; Bao R; Li S; Li H; Cui S; Jin X; Ding H; Geng W; Jiang Y; Xu J; Shang H
J Med Internet Res; 2020 Oct; 22(10):e22388. PubMed ID: 33052132
[TBL] [Abstract][Full Text] [Related]
16. Helping our patients take HIV pre-exposure prophylaxis (PrEP): a systematic review of adherence interventions.
Marcus JL; Buisker T; Horvath T; Amico KR; Fuchs JD; Buchbinder SP; Grant RM; Liu AY
HIV Med; 2014 Aug; 15(7):385-95. PubMed ID: 24580813
[TBL] [Abstract][Full Text] [Related]
17. HIV incidence after pre-exposure prophylaxis initiation among women and men at elevated HIV risk: A population-based study in rural Kenya and Uganda.
Koss CA; Havlir DV; Ayieko J; Kwarisiima D; Kabami J; Chamie G; Atukunda M; Mwinike Y; Mwangwa F; Owaraganise A; Peng J; Olilo W; Snyman K; Awuonda B; Clark TD; Black D; Nugent J; Brown LB; Marquez C; Okochi H; Zhang K; Camlin CS; Jain V; Gandhi M; Cohen CR; Bukusi EA; Charlebois ED; Petersen ML; Kamya MR; Balzer LB
PLoS Med; 2021 Feb; 18(2):e1003492. PubMed ID: 33561143
[TBL] [Abstract][Full Text] [Related]
18. Protocol for a multicenter, real-world study of HIV pre-exposure prophylaxis among men who have sex with men in China (CROPrEP).
Wang H; Zhang Y; Mei Z; Jia Y; Leuba SI; Zhang J; Chu Z; Ding H; Jiang Y; Geng W; Shang H; Xu J
BMC Infect Dis; 2019 Aug; 19(1):721. PubMed ID: 31416439
[TBL] [Abstract][Full Text] [Related]
19. Brief Report: Discrepancies Between Self-Reported Adherence and a Biomarker of Adherence in Real-World Settings.
Hebel S; Kahn-Woods E; Malone-Thomas S; McNeese M; Thornton L; Sukhija-Cohen A; Patani H; Engeran W; Daughtridge G
J Acquir Immune Defic Syndr; 2020 Dec; 85(4):454-457. PubMed ID: 33136744
[TBL] [Abstract][Full Text] [Related]
20. Mobile App (UPrEPU) to Monitor Adherence to Pre-exposure Prophylaxis in Men Who Have Sex With Men: Protocol for a User-Centered Approach to Mobile App Design and Development.
Strong C; Wu HJ; Tseng YC; Yuan CW; Yu YF; Liao JC; Chen YW; Hung YC; Li CW; Huang PH; Ko NY; Ku SW
JMIR Res Protoc; 2020 Dec; 9(12):e20360. PubMed ID: 33258793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
